Three to four quarters of weakness had already worn patience thin.
On a Friday in late October, Colgate Palmolive India found itself at a familiar crossroads that many consumer giants eventually face: the moment when a trusted brand's quarterly numbers force the market to ask whether a stumble is temporary or something deeper. With net profit down 17.2 percent and revenue contracting 6.3 percent year-on-year, shares settled 2 percent lower at ₹2,237.85, leaving analysts divided not merely on price targets but on the nature of the company's challenge itself. The story unfolding in Mumbai's markets is, in essence, an old one — the tension between a company's enduring identity and the pressures of a competitive, duty-distorted present.
- A sharper-than-expected earnings miss — profit down 17.2% and revenue shrinking 6.3% — sent shares sliding as low as ₹2,200.60 before a partial recovery, signalling genuine investor unease.
- The quarter is not an isolated stumble but part of a three-to-four quarter slump, raising uncomfortable questions about whether Colgate's difficulties are cyclical headwinds or signs of structural erosion.
- An inverted duty structure looming in Q3 and intensifying competition are compressing margins even as volume dropped 8.5%, creating a pincer effect that brokerages cannot agree on how to price.
- The analyst community is fractured from sell to buy — Citi's bearish ₹2,100 target sits alongside Motilal Oswal's optimistic ₹2,850, a spread that itself maps the width of the uncertainty.
- Bulls anchor their faith in premiumisation and urban innovation as durable growth engines; bears counter that strategy cannot outrun near-term operating leverage losses and competitive intensity.
Colgate Palmolive India's shares closed down 2 percent on Friday, settling at ₹2,237.85 on the BSE after touching an intraday low of ₹2,200.60. The trigger was a second-quarter earnings report that disappointed on nearly every front: net profit fell 17.2 percent and revenue declined 6.3 percent compared to the same period last year, extending what has become a multi-quarter stretch of underperformance.
The results have drawn sharply divergent responses from brokerages. On the optimistic side, Motilal Oswal maintained a buy rating with a target of ₹2,850, arguing that demand recovery following GST 2.0 implementation will restore momentum in coming quarters. Jefferies similarly held its buy call at ₹2,700, pointing to resilience in the premium segment. Nuvama kept a buy rating but trimmed its target from ₹3,135 to ₹2,870, acknowledging margin pressure from an inverted duty structure expected to weigh further in Q3.
More cautious voices clustered around hold ratings. PL Capital raised its target modestly to ₹2,534, conceding that long-term growth drivers — premium toothpaste brands and science-backed urban innovation — remain intact even as competitive headwinds persist. InCred Equities lowered its target to ₹2,435, and JM Financial held an add rating at ₹2,405.
The most bearish calls came from global houses. Citi issued a sell with a ₹2,100 target, the lowest on the street. Nomura recommended reduce at ₹2,200, flagging an 8.5 percent volume drop and warning that stable margins were masking negative operating leverage. CLSA held at ₹2,130.
What the divergence ultimately reveals is a market genuinely uncertain about Colgate's trajectory — whether its current difficulties are a cyclical passage that premiumisation and innovation will eventually navigate, or the early signal of something more stubborn taking hold.
Colgate Palmolive's stock price fell on Friday, closing down 2 percent after the company reported earnings that disappointed investors. The decline came on the heels of a quarter where net profit contracted by 17.2 percent and revenue shrank 6.3 percent compared to the same period last year. Shares had dipped as low as ₹2,200.60 during the day before settling at ₹2,237.85 on the BSE, down from the previous close of ₹2,288.80.
The weakness in the quarter—part of a broader three to four quarter slump—has left Wall Street and Indian brokerages reading the same data in starkly different ways. Motilal Oswal sees green shoots ahead. The firm believes Colgate is positioned to bounce back in coming quarters as demand improves following the implementation of GST 2.0, and it has maintained a buy rating with a target price of ₹2,850. Jefferies, another bull, points to resilient performance in the premium segment and expects the stock to trade in a range, assigning a buy call at ₹2,700.
But caution dominates the consensus. Nuvama Institutional Equities acknowledges that Colgate's valuation offers some comfort to buyers, yet the firm worries about margin pressure from an inverted duty structure expected in the third quarter, combined with intensifying competition. Nuvama cut its target price from ₹3,135 to ₹2,870 while keeping a buy rating. JM Financial maintained an add rating at ₹2,405. PL Capital retained a hold, raising its target slightly to ₹2,534 from ₹2,453, noting that while the company's long-term growth drivers—premium toothpaste brands and science-backed innovation in urban markets—remain intact, competitive pressure is a persistent headwind. InCred Equities also held its ground with a hold rating, lowering its target to ₹2,435 from ₹2,570.
Global brokerages painted an even more mixed picture. Citi issued a sell rating with a target of ₹2,100, the most bearish call on the street. CLSA maintained a hold at ₹2,130. Nomura recommended reduce at ₹2,200, citing an 8.5 percent drop in volumes and noting that while margins remained stable, negative operating leverage was squeezing profitability.
The divergence reflects genuine uncertainty about whether Colgate's troubles are cyclical or structural. The company faces near-term headwinds from duty inversions and competitive intensity, yet its strategy of driving growth through premiumisation and innovation in urban segments remains theoretically sound. Whether that strategy can overcome current market pressures—and how quickly—is what separates the bulls from the bears.
Notable Quotes
Colgate is well-positioned for a recovery in the coming quarters, with improving demand trends following GST 2.0 implementation— Motilal Oswal
Long-term drivers are intact, led by driving core toothpaste brands and premiumisation through science-backed innovations, while heightened competitive pressure remains a key concern— PL Capital
The Hearth Conversation Another angle on the story
Why did the stock fall so sharply when the earnings miss wasn't catastrophic by historical standards?
Because investors had been hoping for stabilization. Three to four quarters of weakness had already worn patience thin. When you see net profit down 17 percent and revenue down 6 percent, it signals the turnaround isn't happening yet.
The brokerages seem split almost evenly. How do you read that?
It's a genuine fork in the road. Some see GST 2.0 as a catalyst that will unlock demand. Others think competitive intensity and margin pressures are structural problems that won't disappear with a policy change. Both readings are defensible.
What's the inverted duty structure everyone keeps mentioning?
It's a tax quirk that makes certain inputs more expensive than finished goods. In Q3, that's going to squeeze margins further. It's a temporary headwind, but it's real.
Is the premium segment really performing as well as Jefferies claims?
It seems to be holding up better than the mass market. That's actually important—it suggests the brand still has pricing power with affluent consumers. But it's not enough to offset weakness elsewhere.
What would need to happen for the bulls to be right?
Demand would need to pick up materially in the next two quarters, and competitive pricing pressure would need to ease. That's possible, but it requires things outside the company's control to break its way.